Compare Cassava Sciences Inc (FLNA) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nano Dimension Ltd - ADR — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $312.60M). The key difference: Nano Dimension Ltd - ADR is far larger — about 5.9× Cassava Sciences Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NNDM | |
|---|---|---|
Market Cap | $53.14M | $312.60M |
Sector | Health | Technology |
52-Week High | $4.64 | $2.14 |
52-Week Low | $1.09 | $1.21 |
Enterprise Value | -$33.43M | -$96.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Nano Dimension (NNDM) trades at $1.49, down 0.67% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -286.72% and negative cash flow from operations of -$101.28M. Recent news highlights boardroom disputes with shareholder Murchinson and a proposed business combination with Infinite Epigenetics, creating uncertainty around strategic direction.
The outlook remains challenged by persistent cash burn and lack of profitability despite revenue increases. Investment opportunity lies in the company's cash position of $757.96M and low P/B ratio of 0.64, but risks include ongoing operational losses, shareholder activism, and execution risks in strategic initiatives. The stock faces headwinds from negative investor sentiment and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
